protein

Prostatic acid phosphatase/ACPP Protein, Human (354a.a, HEK293, His, solution)

HY-P7817

10 μg;50 μg

240;704 USD

Prostatic acid phosphatase/ACPP Protein, Human (354a.a, HEK293, His, solution)

proteins

HEK293

10 μg;50 μg

240;704 USD

PPAP protein, a nonspecific tyrosine phosphatase, has anticancer and antiproliferative activities. The PPAP protein dephosphorylates a variety of substrates under acidic conditions (pH 4-6), resulting in the inactivation of lysophosphatidic acid in seminal plasma. The PPAP protein is also a common biomarker for prostate cancer and can inhibit tumor development. Prostatic acid phosphatase/ACPP Protein, Human (354a.a, HEK293, His, solution) is the recombinant human-derived Prostatic acid phosphatase/ACPP protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Prostatic acid phosphatase/ACPP Protein, Human (354a.a, HEK293, His, solution) is 354 a.a., with molecular weight of ~50.0 kDa.

Human

PPAP protein (cPAcP), a nonspecific tyrosine phosphatase and prostate epithelial differentiation antigen, is involved in regulating prostate epithelial growth. PPAP dephosphorylates a variety of substrates under acidic conditions (pH 4-6) and leads to the inactivation of lysophosphatidic acid in seminal plasma. It interacts with and dephosphorylates ErbB-2 primarily at Tyr(1221/2), thereby blocking downstream signaling and resulting in reduced cell growth. It also functions as a negative growth regulator of prostate cancer (PCa) cells in part through dephosphorylation of ErbB-2. The PPAP protein is often used as a biomarker for prostate cancer. Inhibition of prostate cancer development through ERBB2 dephosphorylation and inactivation of MAPK-mediated signaling. Therefore, the occurrence of androgen-independent cell proliferation and tumorigenicity is closely related to the reduction of intracellular PPAP protein expression. Intratumoral injection of a PAcP cDNA expression vector inhibits xenograft tumor progression and reduces ErbB-2 tyrosyl phosphate. In prostate cancer and PCa cells with reduced cPAcP, reduced cPAcP leads to activation of ErbB-2 and ERK1/2 signaling.

rHuProstatic acid phosphatase/ACPP, His; Prostatic Acid Phosphatase; PAP; 5'-Nucleotidase; 5'-NT, Ecto-5'-Nucleotidase; Thiamine Monophosphatase; TMPase; ACPP

Greater than 95% as determined by reducing SDS-PAGE

Supplied as a 0.2 μm filtered solution of 20 mM PBS, pH 7.4.

Shipping with dry ice.